Clinical trials have evaluated corticosteroids, specifically prednisone and other glucocorticoids, as a potential treatment for behavioral variant frontotemporal dementia (bvFTD). The rationale stemmed from the hypothesis that neuroinflammation, including microglial activation and elevated pro-inflammatory cytokines, plays a role in FTD pathogenesis, particularly in cases with tau or TDP-43 pathology[@corticosteroids2007].
Frontotemporal dementia represents a group of disorders characterized by progressive degeneration of the frontal and anterior temporal lobes. The behavioral variant (bvFTD) is the most common subtype, presenting with changes in personality, social conduct, and executive function. The diverse pathology underlying FTD—including tau, TDP-43, and FUS inclusions—suggests multiple potential therapeutic targets.
Trial Details
Phase: Phase 2
Status: Completed
Drug: Prednisone (various doses)
Patient Population: Patients with clinically probable bvFTD
Duration: 6-12 months
NCT Number: NCT00138602
Background and Rationale
Neuroinflammation in FTD
Post-mortem studies and PET imaging using TSPO ligands have revealed evidence of neuroinflammation in FTD brains:
Microglial Activation: Activated microglia in frontal and temporal cortices
Cytokine Elevation: Elevated IL-1β, TNF-α, and IL-6 in FTD brain tissue
Correlation with Symptoms: Neuroinflammation severity correlates with behavioral symptoms
...
Overview
Clinical trials have evaluated corticosteroids, specifically prednisone and other glucocorticoids, as a potential treatment for behavioral variant frontotemporal dementia (bvFTD). The rationale stemmed from the hypothesis that neuroinflammation, including microglial activation and elevated pro-inflammatory cytokines, plays a role in FTD pathogenesis, particularly in cases with tau or TDP-43 pathology[@corticosteroids2007].
Frontotemporal dementia represents a group of disorders characterized by progressive degeneration of the frontal and anterior temporal lobes. The behavioral variant (bvFTD) is the most common subtype, presenting with changes in personality, social conduct, and executive function. The diverse pathology underlying FTD—including tau, TDP-43, and FUS inclusions—suggests multiple potential therapeutic targets.
Trial Details
Phase: Phase 2
Status: Completed
Drug: Prednisone (various doses)
Patient Population: Patients with clinically probable bvFTD
Duration: 6-12 months
NCT Number: NCT00138602
Background and Rationale
Neuroinflammation in FTD
Post-mortem studies and PET imaging using TSPO ligands have revealed evidence of neuroinflammation in FTD brains:
Microglial Activation: Activated microglia in frontal and temporal cortices
Cytokine Elevation: Elevated IL-1β, TNF-α, and IL-6 in FTD brain tissue